Resource Summary Report

Generated by RRID on Aug 20, 2026

pGL4.75-KRAS LCS6m

RRID:Addgene_44571
Type: Plasmid

Proper Citation

RRID:Addgene_44571

Plasmid Information

URL: http://www.addgene.org/44571

Proper Citation: RRID:Addgene_44571

Insert Name: KRAS 3'UTR

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Vector Backbone Description: Backbone Marker:Promega; Backbone Size:4281; Vector Backbone:pGL4.75; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Comments: A substitute for pGL3-KRAS LCS6m in Chin et al., 2008.

Plasmid Name: pGL4.75-KRAS LCS6m

Relevant Mutation: The T allele at LCS6 (let-7 complementary site 6) was changed to the G allele (rs61764370 T>G)

Record Creation Time: 20220422T222230+0000

Record Last Update: 20260815T081516+0000

Ratings and Alerts

No rating or validation information has been found for pGL4.75-KRAS LCS6m.

No alerts have been found for pGL4.75-KRAS LCS6m.

Data and Source Information

Source: Addgene

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Ferino A, et al. (2018) MicroRNA therapeutics: design of single-stranded miR-216b mimics to target KRAS in pancreatic cancer cells. RNA biology, 15(10), 1273.

Ling M, et al. (2017) Epigenetic regulation of Runx2 transcription and osteoblast differentiation by nicotinamide phosphoribosyltransferase. Cell & bioscience, 7, 27.

Neu J, et al. (2017) miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS. PloS one, 12(9), e0185028.

Gong Z, et al. (2014) Novel insights into the role of microRNA in lung cancer resistance to treatment and targeted therapy. Current cancer drug targets, 14(3), 241.

Kopp F, et al. (2014) The proto-oncogene KRAS is targeted by miR-200c. Oncotarget, 5(1), 185.